CERRITO MARIA GRAZIA

Ilari, A., Cogliati, V., Sherif, N., Grassilli, E., Ramazzotti, D., Cordani, N., et al. (2024). Differential Expression of NOTCH-1 and Its Molecular Targets in Response to Metronomic Followed by Conventional Therapy in a Patient with Advanced Triple-Negative Breast Cancer. BIOMEDICINES, 12(2) [10.3390/biomedicines12020272]. Detail

Grassilli, E., Cerrito, M. (2023). "Ironing out" fasting-induced persister cancer cells to render chemotherapy effective: is this the solution?. EBIOMEDICINE, 90(April 2023) [10.1016/j.ebiom.2023.104542]. Detail

Cordani, N., Mologni, L., Piazza, R., Tettamanti, P., Cogliati, V., Mauri, M., et al. (2023). TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 24(22) [10.3390/ijms242216294]. Detail

Meazza Prina, M., Gotuzzo, I., Cazzaniga, M., De Bernardi, E., Cafaro, P., Capici, S., et al. (2023). Baseline 18FDG-PET Metabolic Tumour Volume (MTV) as a Potential Predictive Factor of Response to Metronomic Chemotherapy (mCHT) in HR+/HER2- Metastatic Breast Cancer (MBC) Patients (pts). Preliminary Results of the Metro-pet Study. Intervento presentato a: SABCS - San Antonio Breast Cancer Symposium - DEC 06-10, 2022, San Antonio, Texas, USA [10.1158/1538-7445.SABCS22-P6-01-42]. Detail

Cordani, N., Mologni, L., Piazza, R., Cogliati, V., Pepe, F., Capici, S., et al. (2023). Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in Luminal Breast Cancer cells. In Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX (pp.13-21). AACR [10.1158/1538-7445.SABCS22-P1-13-21]. Detail